Saturday, October 12, 2024 from 3:30 PM to 5:00 PM MST at Convention Center North Building / Meeting Room 131
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-24-125-L01-PActivity Type: A Knowledge-Based ActivityThis session will discuss novel approaches to detecting, evaluating, and managing early cognitive changes. The session will review the spectrum of cognitive change in persons at risk for dementia. It will describe the interplay between chronic cardiovascular and cerebrovascular conditions and the risk for cognitive change. It will also explore the utility of biomarker evaluation and amyloid-beta treatments for early-stage cognitive changes in patients with cardio and cerebrovascular considerations.
Learning Objectives1. Discuss approaches to detecting, evaluating, and managing early cognitive changes.
2. Review the spectrum of cognitive changes in persons at risk for dementia.
3. Describe the relationship between chronic cardiovascular disease and risk for cognitive decline.
4. Summarize the clinical pharmacist’s role in patient cardiovascular health to reduce the risk for cognitive impairment.
5. Explain the utility of biomarker evaluation in detection of early cognitive changes.
6. Describe appropriate candidates for amyloid-beta therapies and the real-world application.
 | | Moderator: | Collin M. Clark, Pharm.D., BCGP, BCPS | | Clinical Assistant Professor
University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Buffalo, New York | | View Biography |
|
Early Cognitive Change in Persons at Risk for Dementia3:30 PM to 4:00 PM | | Speaker: | Erica Dominguez, Pharm.D., BCACP | | Assistant Professor, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas | | View Biography |
|
|
Connecting the Dots Between Cardiovascular Disease and Cognitive Impairment4:00 PM to 4:30 PM | | Speaker: | Kristen M. Cook, Pharm.D., BCACP | | Clinical Associate Professor, University of Nebraska Medical Center College of Pharmacy, Omaha, NE | | View Biography |
|
|
Utility of Biomarkers and Amyloid-Beta Therapy for Early-Stage Cognitive Change4:30 PM to 5:00 PM | | Speaker: | Jeffrey T. Sherer, Pharm.D., MPH, BCGP, BCPS | | Clinical Professor, University of Houston College of Pharmacy, Houston, Texas | | View Biography |
|
|